Emergent BioSolutionsNYSE: EBS

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four medical countermeasures (MCMs). These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threats and emergencies against anthrax, smallpox and botulism.

Nvidia Corp NVDA is trading lower Tuesday amid reports that the company faces antitrust charges from French regulators.

GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- In recognition of National Naloxone Awareness Day, Emergent BioSolutions Inc. (NYSE: EBS) is highlighting its ongoing efforts to combat the opioid epidemic in the U.S., including topline results from its new general population awareness survey on consumers' understanding of opioid-related accidental overdose and fentanyl. The results show that there is a high level of awareness that fentanyl is an opioid, and that naloxone can reverse opioid overdoses, including those caused by fentanyl.1 It also found that there are still gaps in certain age groups and populations in understanding the role of naloxone in reversing opioid overdoses related to fentanyl.1

Emergent BioSolutions is making headlines for its plans to lay off workers and shut down some facilities, with 300 employees expected to be impacted, as announced by the company.

Good afternoon, everyone. I will be facilitating today's call.

Emergent BioSolutions announced on Wednesday that it plans to reduce its workforce by around 300 employees and close multiple manufacturing facilities as part of a restructuring effort.

Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.

Emergent BioSolutions Inc. (NYSE:EBS ) Q4 2023 Earnings Conference Call March 6, 2024 5:00 PM ET Company Participants Rich Lindahl - Executive Vice President & Chief Financial Officer Joe Papa - President and Chief Executive Officer Paul Williams - Senior Vice President & Head, Products Business Conference Call Participants Jessica Fye - JPMorgan Frank DiLorenzo - Singular Research Operator Good afternoon, everyone. I'm the operator for today's call.

Emergent Biosolutions (EBS) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.31 per share a year ago.